The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Early results of PHE885, a novel BCMA-directed CAR-T therapy for the treatment of R/R MM
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses a Phase II study investigating PHE885, a novel BCMA-directed CAR-T therapy, for the treatment of relapsed/refractory (R/R) multiple myeloma. Dr Munshi first comments on the methods used to produce this agent, and further highlights some of the early findings of this study. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Advisory Board/Consultant: Adaptive, Abbvie, Amgen, BMS, Janssen, Karyopharm, Legend, Oncopep, Millennium, Novartis, Pfizer DCT
Scientific Founder: Oncopep, DCT
